
Biotechnology
California-based biotechnology company Vical Incorporated (NASDAQ:VICL) released, on Monday, the results of its Phase 2 herpes simplex virus-2 (HSV-2) therapeutic vaccine. Unfortunately, the trial failed to meet its primary endpoint, so the company has decided ... [Read]